⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15042356 | 1.00 | — | — | |
| SCHEMBL21743243 | 1.00 | — | — | |
| SCHEMBL1838790 | 0.83 | SMN1; SMN2 (0.47) | — | |
| SCHEMBL11870833 | 0.82 | HTT (0.41) | — | |
| SCHEMBL15829094 | 0.78 | HTT (0.42) | — | |
| SCHEMBL27663295 | 0.78 | HTT (0.38) | — | |
| SCHEMBL11224853 | 0.77 | CASR (0.36) | — | |
| SCHEMBL16172597 | 0.76 | — | — | |
| SCHEMBL16172598 | 0.76 | — | — | |
| SCHEMBL1487123 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111492-A1 | INHIBITORS OF PARG | 858 THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| WO-2022173756-A1 | ANTIBACTERIAL COMPOUNDS | FORGE THERAPEUTICS, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2021-07-15 | — | — | US | disclosed |
| US-10888554-B2 | Salts of heterocyclic modulators of HIF activity for treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-01-12 | — | — | US | disclosed |
| US-20200171017-A1 | SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-06-04 | — | — | US | disclosed |
| US-10662185-B2 | Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-26 | — | — | US | disclosed |
| US-20190248783-A9 | AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-15 | — | — | US | disclosed |
| US-10208059-B2 | Heterocyclic modulators of HIF activity for treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-02-19 | — | — | US | disclosed |
| US-10167391-B2 | Azo compound, use thereof and method for preparing same | BIONEER CORPORATION (KR) | 2019-01-01 | — | — | US | disclosed |
| US-20180319794-A1 | AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-08 | — | — | US | disclosed |
| EP-2914594-A1 | AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | Bayer Pharma Aktiengesellschaft (DE) | 2015-09-09 | — | — | EP | disclosed |
| US-9126998-B2 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | Bayer Pharma AG (DE) | 2015-09-08 | — | — | US | disclosed |
| US-9018380-B2 | Heterocyclic modulators of HIF activity for treatment of disease | Boar of Regents, The University of Texas System (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140179672-A1 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-06-26 | — | — | US | disclosed |
| US-20140128372-A1 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| WO-2014068099-A1 | AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | WO | disclosed |
| US-20140066424-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center (US) | 2014-03-06 | — | — | US | disclosed |
| WO-2010132015-A1 | NEW COMPOUNDS MODULATING GAMMA-SECRETASE AND THEIR USE IN THE TREATMENT OF ALPHA BETA RELATED PATHOLOGIES, SUCH AS ALZHEIMER'S DISEASE | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| EP-2028228-A2 | Functionalized nanoparticles | Ciba Holding Inc. (CH) | 2009-02-25 | — | — | EP | disclosed |